PALE-40 Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
PALE-40
Pantoprazole Sodium 40mg
PALE-40 is an advanced gastro-protective formulation developed for the rapid healing of mucosal erosion, acid peptic disorders, and gastroesophageal reflux disease (GERD).
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Forms a polyanionic protective barrier coating over inflamed gastric ulcers, preventing enzymatic acid degradation while facilitating tissue re-epithelialization.
Administer on an empty stomach 1 hour before principal meals, or as posology prescribed by the gastroenterologist.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store between 2°C to 8°C or below 25°C as indicated on label. Protect from light.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
PALE-40 features Pantoprazole Sodium 40mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Employed as a first-line therapeuti for PALE-40
PALE-40 has been employed as a first-line therapeutic choice in appropriate cases, yielding measurable improvement in functional daily vitality without adverse reactions. The sealed blister trays maintain tablet hardness and surface finish without chalking. Our medical fraternity trusts this brand for routine outpatients as well as chronic management.
Questions Regarding PALE-40
What is the therapeutic indication and composition of PALE-40?
PALE-40 contains Pantoprazole Sodium 40mg indicated for Peptic Ulcer Disease as formulated by Sygnus Biotech.
What packaging presentations are available for PALE-40?
PALE-40 is supplied in tamper-evident Single Dose Sterile Vial with Ampoule & WFI, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for PALE-40?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for PALE-40 along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
PALE-40 is categorized as Schedule H1 Prescription Drug with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Injection
View all Injection →
SBCEF-S 375MG
Ceftriaxone Sodium 250mg + Sulbactam 125mg Injection
SBCEF-TZ 1.125GM
Ceftriaxone Sodium 1000mg + Tazobactam 125mg